RhumbLine Advisers

RhumbLine Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History

RhumbLine Advisers’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.05K	Sell
2025 Q1	$3.6K	Sell
2024 Q4	$10.6K	Buy
2024 Q3	$18.2K	Buy
2024 Q2	$16.3K	Buy
2024 Q1	$11.3K	Buy
2023 Q4	$4.69K	Buy
2023 Q3	$4.35K	Hold
2023 Q2	$5.16K	Buy